Mode
Text Size
Log in / Sign up
N/A N=51 Randomized Double-blind Treatment

Cognitive Behavioral Suicide Prevention for Psychosis: Aim 2

Suicide · Psychosis

Enrolled (actual)
51
Serious AEs
13.7%
Results posted
Mar 2026
Primary outcome: Primary: Calgary Depression Rating Scale (CDRS) — 18.20; 17.15; 16.09; 15.39 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) (Behavioral); Services as Usual (SAU) (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Michigan
Primary completion
May 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Calgary Depression Rating Scale (CDRS)
18.20; 17.15; 16.09; 15.39; 13.95; 15.83
PRIMARY
Positive and Negative Syndrome Scale (PANSS)
82.72; 75.27; 77.68; 71.69; 71.57; 76.96
PRIMARY
Columbia Suicide Severity Rating Scale (C-SSRS)
2.52; 1.77; 1.45; 1.48; 1.09; 1.52
SECONDARY
Beck Hopelessness Scale
7.04; 7.85; 5.67; 7.0; 4.0; 7.26
SECONDARY
Defeat Scale (D Scale)
31.24; 32.19; 27.57; 28.52; 22.71; 27.61
SECONDARY
The Entrapment Scale
28.12; 22.04; 27.62; 23.83; 18.33; 27.14

Summary

Investigators will evaluate the feasibility and preliminary effectiveness of modified Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) in comparison to services-as-usual (SAU) in a randomized controlled trial. Investigators will recruit adult clients receiving services at a community mental health (CMH) setting who have a schizophrenia spectrum disorder and recent suicidal thoughts or behaviors within 3 months of screening (n=60). Client participants will be screened, enrolled and randomized to the CBSPp or SAU group. A 4-wave design will include quantitative assessments at baseline (T1), 1-month after baseline (T2), 3-months after baseline (T3), and 5-months after baseline (T4) with in-depth qualitative interviews at T3 for a random sample of adults in the CBSPp group (n=10). Providers (n=12) will be trained to deliver CBSPp and be assessed from T1-T3 to evaluate the implementation process, including in-depth qualitative interviews at T3.

Eligibility Criteria

Inclusion Criteria

  • Schizophrenia Spectrum Disorder
  • Suicide ideation and/or attempt within 3 months of screening
  • Ability to speak and read in English
  • 18 to 65 years of age

Exclusion Criteria

  • Requiring emergency care (e.g. imminent plan to harm self) as determined by trained research staff administering the Columbia-Suicide Severity Rating Scale (C-SSRS)
  • Inappropriate for behavioral treatment according to own judgment in consultation with a treating clinician CMH
  • Impaired capacity (cognitive capacity)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05345184). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search